Clinical Trial Update: AMA1-C1/Alhydrogel + CpG 7909 for Malaria [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of the AMA1-C1 malaria vaccine formulated with Alhydrogel and CpG 7909 has completed, evaluating safety and immunogenicity. The study w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• AMA1-C1/Alhydrogel +/- CPG 7909

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Plasmodium Falciparum Malaria | Phase 1 | Status: COMPLETED